ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
update
/
details

Revvity's EUROIMMUN Introduces New Solution for Precise Typing of APOE Gene Linked to Alzheimer's Disease

NextEdge Admin

03 Oct 2024

2 min 13 sec

Revvity, has announced the launch of the EURORealTime™ APOE assay, an in-vitro diagnostic test now available in European countries that accept the CE mark. This new test offers accurate genotyping of the APOE gene, which plays a critical role in assessing a patient’s risk for side effects before beginning anti-amyloid (beta) therapy for Alzheimer's disease.

“With the advent of disease-modifying drugs for Alzheimer’s, a new era of therapy has emerged. However, patients with certain forms of the APOE gene are at significant risk of developing potentially life-threatening side effects known as ARIA (amyloid-related imaging abnormalities), which can cause brain edema or microbleeds,” said Dr. Lars Komorowski, Chief Scientific Officer of EUROIMMUN. “Determining a patient’s APOE genotype before starting therapy is crucial to evaluating their individual risk.”

The real-time EURORealTime APOE PCR test simultaneously detects the three most common APOE forms—E2, E3, and E4. Carriers of the E4 variant are at the highest risk of ARIA during treatment. With the new test, only one reaction is required from a single blood sample to determine the APOE genotype. The assay can be automated to varying degrees using Revvity’s platforms, including the EUROIMMUN PreNAT II™ and chemagic™ 360, with results processed using EURORealTime analysis software.

This APOE genotyping test will provide clinicians with valuable insights, enabling a more personalized and risk-assessed approach to Alzheimer's treatment.